Compounds > vatalanib
Page last updated: 2024-09-04

vatalanib and 2H-pyrazolo[4,3-b]quinoxalin-3-amine

vatalanib has been researched along with 2H-pyrazolo[4,3-b]quinoxalin-3-amine in 1 studies

Compound Research Comparison

Studies
(vatalanib)		Trials
(vatalanib)		Recent Studies (post-2010)
(vatalanib)		Studies
(2H-pyrazolo[4,3-b]quinoxalin-3-amine)		Trials
(2H-pyrazolo[4,3-b]quinoxalin-3-amine)		Recent Studies (post-2010) (2H-pyrazolo[4,3-b]quinoxalin-3-amine)
2764298907

Protein Interaction Comparison

ProteinTaxonomyvatalanib (IC50)2H-pyrazolo[4,3-b]quinoxalin-3-amine (IC50)
Cyclin-dependent kinase 1Homo sapiens (human)9.7
G2/mitotic-specific cyclin-B1Homo sapiens (human)9.7
G2/mitotic-specific cyclin-BMarthasterias glacialis (spiny starfish)0.6
Interferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)6
Cyclin-A2Homo sapiens (human)0.01
G1/S-specific cyclin-E1Homo sapiens (human)5.6
Cyclin-dependent kinase 2Homo sapiens (human)2.805
Glycogen synthase kinase-3 betaHomo sapiens (human)1
Cyclin-dependent-like kinase 5 Homo sapiens (human)0.4
Cyclin-dependent kinase 5 activator 1Homo sapiens (human)0.4
Cyclin-dependent kinase 1Oryzias latipes (Japanese medaka)0.6

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M1

Other Studies

1 other study(ies) available for vatalanib and 2H-pyrazolo[4,3-b]quinoxalin-3-amine

ArticleYear
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
    Proceedings of the National Academy of Sciences of the United States of America, 2007, Dec-18, Volume: 104, Issue:51

    Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases

2007